Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Cohen Milstein continues lead plaintiff Search for Zenas BioPharma (ZBIO) securities fraud class action. Contact Molly Bowen, Esq. at 1 (202) 408-4600.
-
SCR Partners continues its growth with addition of Lisa Kampf as SVP
-
SuRo Capital Portfolio Investment, CoreWeave, Completes Largest Tech IPO Since 2021 SuRo Capital Portfolio Investment, OpenAI, Closes Largest Venture Raise with $300 Billion Valuation Net Asset...
-
Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit
Cohen Milstein reminds Zenas BioPharma (ZBIO) investors of an opportunity to lead a securities fraud class action. Lead plaintiff deadline - June 16, 2025.
-
Cohen Milstein seeks Zenas BioPharma (ZBIO) investors to join and/or lead class action to hold Zenas BioPharma accountable for IPO-related fraud.
-
PRINCETON, NEW JERSEY, April 30, 2025 (GLOBE NEWSWIRE) -- Real Asset Acquisition Corp. (Nasdaq: RAAQ) (the “Company”) today announced the closing of its initial public offering of 17,250,000 units,...
-
PRINCETON, NJ, April 28, 2025 (GLOBE NEWSWIRE) -- Digital Asset Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00...
-
PRINCETON, NJ, April 28, 2025 (GLOBE NEWSWIRE) -- Real Asset Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00...
-
Palm Beach, FL, April 25, 2025 (GLOBE NEWSWIRE) -- New Providence Acquisition Corp. III (the “Company”) announced today the closing of its initial public offering of 30,015,000 units, which includes...
-
Investors who purchased stock in Zenas BioPharma, Inc. (NASDAQ: ZBIO) September 2024 IPO and lost money should call Cohen Milstein to join a class action.